Australasian Business Intelligence - Weight-loss medication under scrutiny.
By Rebecca Jenkins
LANCET A review of anti-obesity drugs suggests their use is limited by modest efficacy and the low numbers of patients who persist with treatment.
The analysis, which included orlistat (Xenical), sibutramine (Reductil) and rimonabant (Acomplia), concluded that studies of anti-obesity drugs to date were notable for their high attrition rates and lack of data on major obesity-related morbidity.
Rimonabant, the first of the endocannabinoid receptor antagonists, is not yet available in Australia.
Related Results
AMA on offensive over Xenical ads.
Keep taking the pills
TV program walks as pharma co fined.
Nutley, N.J.-Based Drugmaker Pioneers Fat-Fighting Pill.
Studies Show Xenical(R) Can Help Tackle the Cardiovascular Time Bomb Known as…
“Anti-obesity drug trials powered to show clinically …
Read the rest of this article with a Free Trial at HighBeam Research.
